The concept of prion-like transmission has shadowed tau research for years. Prions, the proteinaceous infectious agents behind Creutzfeldt-Jakob disease and bovine spongiform encephalopathy, propagate by coaxing normally folded prion proteins into the abnormal, misfolded state. Distinct folding patterns of the abnormal protein behave as different prion strains, each carrying its own incubation period and clinical profile. Tau, a microtubule-binding protein implicated in more than twenty neurodegenerative diseases, forms amyloid-like filaments in patient brains and has long been suspected of spreading through a similar templating mechanism. Cryo-electron microscopy studies have already shown that each tauopathy is defined by a unique tau filament fold, and that the same fold recurs across different brain regions within a single patient, implying that specific structures amplify and propagate as disease advances.

What remained unproven was whether tau filaments of different structures genuinely cause distinct disease pathologies through prion-like mechanisms, and whether those structural signatures survive the journey from cell to cell. The new study, titled Prion-like transmission of human tau strains in the mouse brain and published on September 30, 2026, answers both questions with unusual clarity. The work was a collaboration involving Dr. Aki Shimozawa and Dr. Airi Tarutani in Tokyo alongside Dr. Sofia Lövestam, Dr. Michel Goedert, and Dr. Sjors H.W. Scheres in Cambridge, with Lövestam, Shimozawa, and Tarutani serving as co-first authors.

The experimental design was elegantly simple. Tau filaments were extracted from the brains of Alzheimer’s disease and corticobasal degeneration patients and injected into the striatum of wild-type mice aged six to eighteen weeks. No genetic engineering was involved; the animals carried only their own normal mouse tau. Within six to nine months after injection, the mice developed tau pathologies that closely resembled those seen in the patient brains from which the seeds had come. Immunohistochemical staining revealed that the pathology had spread well beyond the injection site, reaching the cerebral cortex, the corpus callosum, and other distant brain regions, mirroring the progressive spread of tau lesions in human disease.

A critical series of controls established that the accumulating pathology was not simply the injected material persisting in the brain. Time-course analysis showed that the human tau filaments degraded and disappeared within approximately one week of injection. Endogenous tau accumulation began to re-emerge one to three months later, and by six to nine months the disease-characteristic lesions had fully appeared. Immunoblotting of the sarkosyl-insoluble fractions, a biochemical preparation that isolates aggregated tau, showed that the insoluble tau in the mouse brains reacted with an antibody specific to mouse tau, called mTau, but not with HT7, an antibody specific to human tau. The pathology, in other words, was built entirely from the mice’s own protein, assembled under the direction of the transient human seeds.

The most consequential finding came from cryo-electron microscopy, a technique that freezes biological molecules in place and resolves their three-dimensional structures at atomic scale. Filaments harvested from the mouse brains adopted the exact same folded structures as the injected human tau filaments. In mice seeded with Alzheimer’s-derived tau, the majority of amplified filaments were helical structures composed of two twisted protofilaments, resolved at 3.6 angstroms and shown to be identical to the paired helical filaments characteristic of Alzheimer’s patient brains. In mice seeded with corticobasal degeneration-derived tau, two filament types emerged: roughly seventy percent were single protofilaments and thirty percent were doublets of two twisted protofilaments, with the single protofilaments resolved at 3.4 angstroms and proven identical to Type 1 filaments found in corticobasal degeneration patients.

Equally revealing was how the two seed types produced visibly different diseases in the same kind of host. Mice injected with Alzheimer’s-derived tau developed pathology concentrated in the cell bodies and processes of neurons. Mice injected with corticobasal degeneration-derived tau showed tau accumulation not only in neurons but also in glial cells, forming structures that resembled astrocytic plaques and coiled bodies, the hallmark lesions used to diagnose corticobasal degeneration in human neuropathology. Astrocytic plaques are tau deposits in the distal processes of astrocytes, while coiled bodies are fibrous, comma-shaped inclusions in oligodendrocytes. The structural identity of the seed therefore determined not just the shape of the filaments but which cell types would be affected and how the pathology would be distributed across the brain.

Immunoelectron microscopy of the insoluble fractions confirmed the picture, revealing abundant filament structures decorated by both mTau and AT8 antibodies, markers of mouse tau and pathological phosphorylation respectively. Further biochemical profiling with antibodies recognizing the C-terminal region of tau showed that the aggregates formed by Alzheimer’s-derived and corticobasal degeneration-derived seeds carried distinct biochemical signatures, reinforcing the conclusion that the injected structures had imposed their identities on the newly formed mouse tau. At the ultrastructural level, the Alzheimer’s-seeded mice produced filaments with the tight twisted configuration typical of that disease, while the corticobasal degeneration-seeded mice produced filaments with a longer twist.

The implications reach well beyond the laboratory. These findings provide concrete evidence that tau propagates through the brain the way prion strains do, using filament seeds as structural templates that convert normal protein into copies of themselves while preserving their characteristic folds through successive rounds of amplification and cell-to-cell transmission. Because the mouse model recapitulates disease-specific pathology without any genetic manipulation, it offers researchers a powerful and physiologically faithful platform for dissecting how different tau filament structures produce different diseases, and for testing interventions designed to block seeding, spread, or specific filament conformations.

For the millions of people affected by Alzheimer’s disease and related tauopathies, the study points toward a new class of therapeutic logic. If disease progression depends on tau strains templating their own propagation, then drugs that stabilize normal tau, block filament uptake, or disrupt the templating surface could halt the spread of pathology even after it has begun. The research was supported by the Tokyo Metropolitan Government, the Japan Agency for Medical Research and Development, the Japan Science and Technology Agency, and the Japan Society for the Promotion of Science KAKENHI program, and all animal experiments were approved by the Animal Care and Use Committee of the Tokyo Metropolitan Institute of Medical Science. Patient brain tissue was provided by collaborating institutions across Japan and the University of Manchester, a reminder that this advance in molecular neuroscience rests on the generosity of patients and families who donated tissue for research.

Subject of Research: Prion-like transmission of disease-specific tau filament structures in the mouse brain

Article Title: Demonstration of prion-like transmission of tau in the mouse brain—elucidating the mechanisms behind disease-specific pathogenesis—

Article References: Demonstration of prion-like transmission of tau in the mouse brain—elucidating the mechanisms behind disease-specific pathogenesis—. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: tau, prion-like transmission, Alzheimer's disease, corticobasal degeneration, cryo-electron microscopy, neurodegeneration, tauopathies, protein aggregation, mouse model, amyloid filaments, seeding, Nature

Tau is a microtubule-associated protein that normally stabilizes the internal scaffolding of neurons. In Alzheimer’s disease and a family of related disorders collectively termed tauopathies, tau detaches from microtubules, misfolds, and polymerizes into paired helical and straight filaments that populate neurofibrillary tangles. For decades, these filaments were viewed through the lens of light and conventional electron microscopy, which revealed their overall morphology but not the atomic contacts that hold them together. The advent of cryo-electron microscopy changed that. By freezing thousands of filament samples in vitreous ice and computationally averaging images of countless molecular copies, researchers have resolved the ordered cores of tau filaments from Alzheimer’s disease, chronic traumatic encephalopathy, corticobasal degeneration, Pick’s disease, and several rarer conditions, each with a distinct fold.

These structures established a powerful principle: the fold of the filament core acts as a molecular signature of disease. Alzheimer’s disease tau filaments adopt one characteristic cross-beta architecture, while the filaments of other tauopathies adopt different folds, even though the tau protein sequence is the same. The core, however, is only part of the story. Large regions of the tau molecule remain disordered and invisible in cryo-EM maps, and the filaments carry a dense cargo of post-translational modifications, including phosphorylation, acetylation, truncation, and ubiquitination, many of which sit outside the resolved core. Whether these peripheral modifications merely decorate the filament or actively participate in determining its structure has been an open question.

The new work addresses this question directly by comparing tau filaments from Alzheimer’s disease with those from vacuolar tauopathy, a rare and recently characterized neurodegenerative condition marked by vacuolar changes in the brain and abundant tau inclusions. Using cryo-electron microscopy, the researchers determined the structures of tau filaments extracted from the brains of affected individuals, and then examined how these filaments behave in biological systems. A central result of the study is that tau fibrils from Alzheimer’s disease and from vacuolar tauopathy exhibit distinct seeding patterns in vivo. In other words, when these two types of filaments act as templates for the recruitment of soluble tau, they do not induce the same downstream aggregation behavior, indicating that their structural differences carry functional consequences for the propagation of pathology.

The most surprising structural insight concerns polyubiquitin. Tau filaments in many tauopathies are heavily ubiquitinated, a modification generally interpreted as a cellular tagging system that marks aggregates for degradation by the proteasome or for clearance by autophagy. In the filaments of vacuolar tauopathy, the researchers found that polyubiquitin chains are positioned differently relative to the filament core than in Alzheimer’s disease filaments. Crucially, this repositioning of polyubiquitin is associated with a shift in the protofilament interface, the set of contacts through which the two protofilaments that make up the fibril grip one another. A change at this interface means a change in the overall fold of the filament, altering which tau residues face the solvent and which are buried in the interior of the assembly.

This observation carries significant mechanistic weight. It demonstrates that a covalent modification attached outside the ordered core can exert enough structural influence to remodel the core itself. The polyubiquitin chains, though not part of the cross-beta spine, appear to constrain or redirect how protofilaments associate, effectively selecting an alternative filament fold. From a structural biology standpoint, this expands the concept of the tau filament from a self-determined protein polymer to a composite assembly whose architecture depends on both the tau sequence and the modifications it accrues in the diseased brain. The ordered core and its peripheral cargo are not independent; they are structurally coupled.

The in vivo seeding experiments reinforce the biological relevance of these structural differences. Seeding refers to the ability of an aggregate to template the misfolding of soluble tau, and it underlies the stereotyped spread of tau pathology through the brain along neural connections. If Alzheimer’s disease and vacuolar tauopathy filaments seed differently in living tissue, then the structural variants identified by cryo-EM are not laboratory curiosities but determinants of how disease propagates. Distinct folds may preferentially recruit distinct tau conformations, replicate with different efficiencies, or encounter different barriers to cellular uptake and intercellular transmission. This provides a structural framework for understanding why different tauopathies follow different clinical and pathological courses despite sharing the same aggregating protein.

The findings also have implications for therapeutic development. Several experimental treatments for Alzheimer’s disease and related disorders aim to clear tau aggregates or block their seeding, including immunotherapies with anti-tau antibodies and small molecules designed to stabilize non-pathogenic tau conformations. If the pathological filament structure varies between diseases, and even between molecular subpopulations within a single disease depending on ubiquitination state, then therapies will need to account for this structural heterogeneity. An antibody or inhibitor optimized against the Alzheimer’s disease filament fold may bind poorly to the vacuolar tauopathy fold, and vice versa. Conversely, the exposed polyubiquitin chains themselves could represent disease-specific epitopes or drug targets, offering a way to selectively recognize or destabilize particular filament variants.

More broadly, the study contributes to an evolving view of neurodegenerative disease in which the structural strain of an aggregate, not merely the identity of the aggregating protein, defines the disease entity. This concept, sometimes described as the prion-like strain hypothesis, has gained support from the growing catalogue of distinct filament folds resolved by cryo-EM across amyloid-beta, alpha-synuclein, and TDP-43 aggregates as well as tau. The demonstration that polyubiquitin repositioning can shift the protofilament interface adds a new layer to this framework: the strain landscape is not only diverse but malleable, shaped by the cellular environment and the modification state of the protein. Changes in the ubiquitin-proteasome system that accompany aging or disease could therefore, in principle, nudge tau filaments between alternative structural states.

Many questions remain. The precise atomic details of how polyubiquitin contacts the filament surface and transmits its influence to the protofilament interface will require further high-resolution analysis, and it is not yet clear whether similar modification-driven remodeling occurs in other tauopathies or in filaments carrying other modifications such as phosphorylation. It also remains to be determined whether repositioned polyubiquitin alters filament stability, clearance rates, or interactions with cellular quality-control machinery. Nevertheless, the central conclusion stands on firm ground: modifications outside the ordered core can remodel tau fibril ultrastructure, and the resulting structural variants seed differently in vivo. For a field that has long treated pathological filaments as static end products of neurodegeneration, the message is that these assemblies are dynamic, environmentally responsive structures whose architecture is written jointly by the protein sequence and the cell’s modification machinery. Understanding that interplay may prove essential for diagnosing tauopathies accurately and for designing interventions that target the right molecular shape in the right disease.

Subject of Research: Structural remodeling of pathological tau filaments by polyubiquitin repositioning in Alzheimer's disease and vacuolar tauopathy

Article Title: Repositioning of polyubiquitin alters the pathologic tau filament structure

Article References: Watanabe, R., Creekmore, B. C., Darwich, N. F., Smith, C. L., Xu, H., Baltazar, A., Salphati, S., Changolkar, L., Hoxha, K., Zhang, B., O’Rourke, C. M., Burslem, G. M., Lee, V. M.-Y., Chang, Y.-W., & Lee, E. B. (2026). Repositioning of polyubiquitin alters the pathologic tau filament structure. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01879-4

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01879-4

Keywords: tau filaments, polyubiquitin, cryo-electron microscopy, Alzheimer's disease, vacuolar tauopathy, protofilament interface, neurodegeneration, seeding, post-translational modification, protein aggregation, amyloid strains, structural biology